



VPI/99-06 CON

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Salituro et al.
Serial No.: 10/008,277
Filing Date: December 3, 2001 (03.12.01)
For: INHIBITORS OF c-JUN N-TERMINAL
KINASES

Cambridge, Massachusetts
April 16, 2002

Hon. Assistant Commissioner
For Patents
Washington, D.C. 20231

Attention: Application Processing Division,
Special Processing and Correspondence Branch

TRANSMITTAL LETTER FOR PRELIMINARY AMENDMENT

Sir:


Transmitted herewith are the following
materials relating to the above-identified application:

1. Transmittal letter for Preliminary
Amendment
2. Preliminary Amendment
3. Certificate of Mailing
4. Return Receipt Postcard

Applicants believe that no additional fees are
due at this time, however the Commissioner is hereby
authorized to charge payment of additional fees required
under 37 C.F.R. § 1.16 in connection with the paper

transmitted herewith, or credit any overpayment of same,
to Deposit Account No. 50-0725. A duplicate copy of this
transmittal letter is transmitted herewith.

Respectfully submitted,



April 16, 2002
Date

Andrea L.C. Robidoux
(Reg.No. 47,902)
Agent for Applicants
C/O Vertex Pharmaceuticals Inc.
130 Waverly Street
Cambridge, MA 02139-4242
Tel: (617) 444-6731
Fax: (617) 444-6483



#6/c

VPI/99-06 CON

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner: Not Yet Assigned
Group Art Unit: Not Yet Assigned
Applicant: Salituro, Francesco, et al.
Serial No.: 10/008,277
Filing Date: December 3, 2001
For: INHIBITORS OF c-JUN N-TERMINAL
KINASES (JNK)

Cambridge, Massachusetts
April 16, 2002

Hon. Assistant Commissioner
For Patents
Washington, D.C. 20231

PRELIMINARY AMENDMENT

Sir/Madam:

Prior to examination on the merits, please
amend the above-identified application as follows:

IN THE SPECIFICATION:

Please replace the paragraph on page 26, lines
8-17 with the following replacement paragraph:

"The construct was prepared by PCR using
deoxyoligonucleotides .

5' GCTCTAGAGCTCCATGGGCAGCAAAAGCAAAGTTGACAA 3' [SEQ ID NO:
1] (forward primer with initiation codon underlined) and
5' TAGCGGATCCTCATTTCTGAATTCATTACTTCCTTGTA 3' [SEQ ID NO:
2] (reverse primer with stop codon underlined)

as primers and was confirmed by DNA sequencing. Control
experiments indicated that the truncated JNK3 protein had
an equivalent kinase activity towards myelin basic